Rani Therapeutics Holdings (RANI) Net Income towards Common Stockholders (2020 - 2025)
Historic Net Income towards Common Stockholders for Rani Therapeutics Holdings (RANI) over the last 6 years, with Q3 2025 value amounting to -$7.9 million.
- Rani Therapeutics Holdings' Net Income towards Common Stockholders rose 3779.28% to -$7.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$47.6 million, marking a year-over-year increase of 1332.74%. This contributed to the annual value of -$56.6 million for FY2024, which is 1664.48% up from last year.
- Rani Therapeutics Holdings' Net Income towards Common Stockholders amounted to -$7.9 million in Q3 2025, which was up 3779.28% from -$11.2 million recorded in Q2 2025.
- Rani Therapeutics Holdings' Net Income towards Common Stockholders' 5-year high stood at -$5.5 million during Q2 2021, with a 5-year trough of -$28.7 million in Q3 2021.
- In the last 5 years, Rani Therapeutics Holdings' Net Income towards Common Stockholders had a median value of -$14.1 million in 2023 and averaged -$14.4 million.
- Per our database at Business Quant, Rani Therapeutics Holdings' Net Income towards Common Stockholders plummeted by 89549.08% in 2021 and then soared by 4352.26% in 2022.
- Over the past 5 years, Rani Therapeutics Holdings' Net Income towards Common Stockholders (Quarter) stood at -$13.3 million in 2021, then crashed by 30.57% to -$17.4 million in 2022, then rose by 19.09% to -$14.1 million in 2023, then decreased by 11.86% to -$15.7 million in 2024, then skyrocketed by 49.66% to -$7.9 million in 2025.
- Its Net Income towards Common Stockholders was -$7.9 million in Q3 2025, compared to -$11.2 million in Q2 2025 and -$12.7 million in Q1 2025.